Takeda's Oncology Discovery Strategy (Q26829607)

scientific article

Language	Label	Description	Also known as
English	Takeda's Oncology Discovery Strategy	scientific article

Statements

instance of

1 reference

Takeda's Oncology Discovery Strategy (English)

1 reference

B. DeSchuytner

1

1 reference

stated in

Crossref

K. Kuvalanka

series ordinal

2

1 reference

stated in

Crossref

B. Hibner

series ordinal

3

1 reference

stated in

Crossref

J. Bolen

series ordinal

4

1 reference

stated in

Crossref

language of work or name

1 reference

April 2013

1 reference

stated in

PubMed

published in

Japanese Journal of Clinical Oncology

1 reference

stated in

PubMed

volume

43

1 reference

stated in

PubMed

issue

4

1 reference

stated in

PubMed

page(s)

357-61

1 reference

stated in

PubMed

cites work

Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT023

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT023

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Will the ubiquitin system furnish as many drug targets as protein kinases?

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT023

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT023

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT023

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT023

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Intra-tumour heterogeneity: a looking glass for cancer?

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT023

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT023

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Proteasome inhibitors in multiple myeloma: 10 years later

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT023

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT023

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT023

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic administration of the metastin/kisspeptin analog KISS1-305 or the investigational agent TAK-448 suppresses hypothalamic pituitary gonadal function and depletes plasma testosterone in adult male rats.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT023

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Leuprolide acetate: a drug of diverse clinical applications

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1093%2FJJCO%2FHYT023

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

0 references

1 reference

Takeda's Oncology Discovery Strategy (Q26829607)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Takeda's Oncology Discovery Strategy (Q26829607)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Search